Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?

Sanchez de Toledo J, Gunawardena S, Munoz R, Orr R, Berry D, Sonderman S, Krallman S, Shiderly D, Wang L, Wearden P, Morell VO, Chrysostomou C.

Cardiol Young. 2010 Apr;20(2):138-43. doi: 10.1017/S1047951109990564. Epub 2010 Mar 4.

PMID:
20199704
2.

Enoxaparin use in the neonatal intensive care unit: experience over 8 years.

Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS.

Pharmacotherapy. 2007 Sep;27(9):1263-71.

PMID:
17723080
3.

Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.

Hicks JK, Shelton CM, Sahni JK, Christensen ML.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):943-51. doi: 10.1345/aph.1R116. Epub 2012 Jul 24.

PMID:
22828970
4.

Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.

Michaels LA, Gurian M, Hegyi T, Drachtman RA.

Pediatrics. 2004 Sep;114(3):703-7.

PMID:
15342842
5.

Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.

Bauman ME, Black KL, Bauman ML, Belletrutti M, Bajzar L, Massicotte MP.

Thromb Res. 2009 Apr;123(6):845-7. doi: 10.1016/j.thromres.2008.09.001. Epub 2008 Nov 26.

PMID:
19038418
6.

An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.

Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD.

J Pediatr Hematol Oncol. 2004 Sep;26(9):561-6.

PMID:
15342982
7.

Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.

Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P.

Br J Haematol. 2010 Jun;149(5):734-8. doi: 10.1111/j.1365-2141.2010.08163.x. Epub 2010 Mar 21.

PMID:
20346012
8.

Experience with intravenous enoxaparin in critically ill infants and children.

Crary SE, Van Orden H, Journeycake JM.

Pediatr Crit Care Med. 2008 Nov;9(6):647-9. doi: 10.1097/PCC.0b013e31818d1920.

PMID:
18838932
9.

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Lim W, Dentali F, Eikelboom JW, Crowther MA.

Ann Intern Med. 2006 May 2;144(9):673-84.

PMID:
16670137
10.

Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?

Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, Hülsmann M, Spitzauer S, Pabinger I, Heinz G.

Crit Care Med. 2003 May;31(5):1405-9.

PMID:
12771610
11.

Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.

Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA.

J Trauma. 2009 Jun;66(6):1509-15; discussion 1515-7. doi: 10.1097/TA.0b013e3181a51e33.

PMID:
19509608
12.

Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.

Corder A, Held K, Oschman A.

Pediatr Blood Cancer. 2014 Jun;61(6):1063-7. doi: 10.1002/pbc.24899. Epub 2013 Dec 20.

PMID:
24375987
13.

Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.

Vincent PD, Albert M, Champagne MC, Zikos T, Boulanger I, Blais L, Williamson DR.

J Crit Care. 2011 Aug;26(4):347-51. doi: 10.1016/j.jcrc.2011.02.003. Epub 2011 Mar 30.

PMID:
21454037
14.

Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.

Lin H, Faraklas I, Saffle J, Cochran A.

J Trauma. 2011 Dec;71(6):1557-61. doi: 10.1097/TA.0b013e31823070f9.

PMID:
22027887
15.

Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.

Schloemer NJ, Abu-Sultaneh S, Hanson SJ, Yan K, Hoffmann RG, Punzalan RC, Havens PL.

Pediatr Crit Care Med. 2014 Sep;15(7):e294-9. doi: 10.1097/PCC.0000000000000169.

PMID:
24901803
16.

Optimal dose of enoxaparin in critically ill trauma and surgical patients.

Rutherford EJ, Schooler WG, Sredzienski E, Abrams JE, Skeete DA.

J Trauma. 2005 Jun;58(6):1167-70.

PMID:
15995464
17.

Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.

Ludwig KP, Simons HJ, Mone M, Barton RG, Kimball EJ.

Ann Pharmacother. 2011 Nov;45(11):1356-62. doi: 10.1345/aph.1Q313. Epub 2011 Oct 18.

PMID:
22009998
18.

Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.

Andrade-Campos MM, Montes-Limón AE, Fernandez-Mosteirin N, Salvador-Osuna C, Torres M, Lucia-Cuesta JF, Rubio-Felix D.

Blood Coagul Fibrinolysis. 2013 Mar;24(2):194-8. doi: 10.1097/MBC.0b013e32835b72b8.

PMID:
23358201
19.

Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.

Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M.

J Pediatr. 1996 Mar;128(3):313-8.

PMID:
8774496
20.

Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients.

Streif W, Goebel G, Chan AK, Massicotte MP.

Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F365-70.

Supplemental Content

Support Center